Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market

Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market February 21, 2025, Shanghai – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic […]

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization -Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance -Marks a key step forward for the world’s first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic […]

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug Product, […]

Chime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing

Chime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing October 28, 2024, Shanghai, China – Chime Biologics, a leading global CDMO that enables its partners’success in biologics, today announced a strategic collaboration with MedPacto, a South Korean clinically staged company listed on KOSDAQ (235980). MedPacto, known for […]

Chime Biologics congratulates Hope Medicine on HMI-115’s CDE Breakthrough Therapy Designation

Chime Biologics congratulates Hope Medicine on HMI-115’s CDE Breakthrough Therapy Designation Not available.

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event September 30, 2024, Wuhan – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, successfully hosted the “Fuel BioGrowth Chime Day” event on September 27 at the East Lake Hotel in Wuhan. The event gathered top key opinion leaders (KOLs) and […]

A Brief introduction on the Challenges and Strategies in Antibody Drug Production

A Brief introduction on the Challenges and Strategies in Antibody Drug Production No content available

pilot-plant-of-chime-biologics

 pilot-plant-of-chime-biologics No content available

Going Global – Chime Biologics Embraces Innovation and Quality with Partners

Going Global-Chime Biologics Embraces Innovation and Quality with Partners Foreign biopharmaceutical companies seek CDMO partners with long-term prospects, technology levels, and quality systems aligned with international standards. Jimmy Wei, President of Chime Biologics, highlighted that the company’s competitive edge arises from ensuring product quality, leveraging efficiencies, and maintaining stringent cost controls. July 5, 2024, Shanghai, […]

categoryidArraymk-test